Immunotherapies targeting tau protein have emerged as a promising approach in the treatment of AD, given the pivotal role of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau) in the pathogenesis of the disease. Here, MAPT is linked to Alzheimer disease.